The prognostic impact of tumour NSD2 expression in advanced prostate cancer. Academic Article uri icon

Overview

abstract

  • Purpose: To assess the prognostic significance of the nuclear receptor binding SET protein 2 (NSD2), a co-activator of the NFkB-pathway, on tumour progression in patients with advanced prostate cancer (PCa).Methods: We retrospectively assessed NSD2 expression in 53 patients with metastatic and castration-resistant PCa. Immunohistochemical staining for NSD2 was carried out on specimen obtained from palliative resection of the prostate. Univariable and multivariable analyses were performed to assess the association between NSD2 expression and PCa progression.Results: Of the 53 patients, 41 had castration-resistant PCa and 48 men had metastases at time of tissue acquisition. NSD2 expression was increased in tumour specimen from 42 patients (79.2%). In univariable Cox regression analyses, NSD2 expression was associated with PSA progression, progression on imaging and overall survival (p = 0.04, respectively). In multivariable analyses, NSD2 expression did not retain its association with these endpoints.Conclusions: NSD2 expression is abnormal in almost 80% of patients with advanced PCa. Expression levels of this epigenetic regulator are easily detected by immunohistochemistry while this biomarker exhibited prognostic value for PCa progression and death in univariable analysis. Further studies on NSD2 involvement in PCa proliferation, progression, metastasis and resistance mechanisms are needed.

publication date

  • March 2, 2020

Research

keywords

  • Biomarkers, Tumor
  • Histone-Lysine N-Methyltransferase
  • Prostate
  • Prostatic Neoplasms
  • Repressor Proteins

Identity

Scopus Document Identifier

  • 85080864788

Digital Object Identifier (DOI)

  • 10.1080/1354750X.2020.1734861

PubMed ID

  • 32091270

Additional Document Info

volume

  • 25

issue

  • 3